CASE REPORT article

Front. Oncol.

Sec. Hematologic Malignancies

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1586454

"Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?"

Provisionally accepted
EVGENIA  VERROUEVGENIA VERROU1*IOANNA  DIAMANTIIOANNA DIAMANTI1ASIMINA  FYLAKTOUASIMINA FYLAKTOU2AIKATERINI  DAIOUAIKATERINI DAIOU1DIMITRA  DALAMPIRADIMITRA DALAMPIRA1XANTHIPPI  DIMITRIADOUXANTHIPPI DIMITRIADOU1VASSILIKI  TARAVASSILIKI TARA1ELISSAVET  KARADRAKONTIELISSAVET KARADRAKONTI1AGGELIKI  SEVASTOUDIAGGELIKI SEVASTOUDI1THEODORA  TRIANTAFYLLOUTHEODORA TRIANTAFYLLOU1NIKOLAOS  KARAMPATZAKISNIKOLAOS KARAMPATZAKIS1THEODOSIA  PAPADOPOULOUTHEODOSIA PAPADOPOULOU1EFTHYMIA  VLACHAKIEFTHYMIA VLACHAKI2EMMANOUIL  SINAKOSEMMANOUIL SINAKOS2EIRINI  KATODRITOUEIRINI KATODRITOU1GEORGIA  GIOULAGEORGIA GIOULA3
  • 1Theageneio General Hospital, Thessaloniki, Greece
  • 2Department of Immunology, Hippokration General Hospital, Thessaloniki, Greece
  • 3Aristotle University of Thessaloniki, Thessaloniki, Central Macedonia, Greece

The final, formatted version of the article will be published soon.

The sequential occurrence of diffuse large B-cell lymphoma (DLBCL) in a patient diagnosed with classical Hodgkin lymphoma (cHL) or vice versa represents a rare situation. In parallel, human leukocyte antigen (HLA) has been studied extensively about rising susceptibility in various lymphomas. Herein, we present clinical characteristics, the outcome and the results of HLA class-I and class-II investigation in patients sequentially diagnosed with the above-mentioned combination of lymphomas. We describe 8 patients (6 males/2 females) with median age at diagnosis of first and second lymphomas of 45.5 years (range: 25-74 years) and 57.5 years (range: 30-83 years), respectively. The median interval between the first and the second diagnosis was 6.5 years (range: 4-22 years). Regarding HLA investigation, we observed that four of our patients were HLA-DQB1*03:01 positive. Interestingly, three of our patients displaying this HLA allele developed a third lymphoma. Notably, we observed that the HLA profile of three other patients revealed the presence of HLA-B*35:03. Interestingly, both above-mentioned HLA alleles have been associated with autoimmune manifestations. Although the presence of certain HLA alleles in our patients could be coincidental, our results suggest that HLA typing may be a field of investigational interest regarding patients with sequential lymphomas.

Keywords: sequential lymphomas, DLBCL, CHL, Hla system, Autoimmunity

Received: 02 Mar 2025; Accepted: 09 Jun 2025.

Copyright: © 2025 VERROU, DIAMANTI, FYLAKTOU, DAIOU, DALAMPIRA, DIMITRIADOU, TARA, KARADRAKONTI, SEVASTOUDI, TRIANTAFYLLOU, KARAMPATZAKIS, PAPADOPOULOU, VLACHAKI, SINAKOS, KATODRITOU and GIOULA. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: EVGENIA VERROU, Theageneio General Hospital, Thessaloniki, Greece

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.